非诺贝特降胆固醇机制的研究进展  

Advances in research on mechanism of the cholesterol-lowering effect of fenofibrate

作　　者：翟婷 李世云 黄华安[2] ZHAI Ting;LI Shi-yun;HUANG Hua-an(Graduate School,Zunyi Medical University,Zunyi 563003,Guizhou,CHINA;Department of Endocrinology,the Affiliated Hospital of Chengdu University,Chengdu 610081,Sichuan,CHINA)

机构地区：[1]遵义医学院,贵州遵义563003 [2]成都大学附属医院,四川成都610081

出　　处：《海南医学》2018年第24期3526-3529,共4页Hainan Medical Journal

摘　　要：非诺贝特是第三代苯氧芳酸衍生物调脂药,是目前市场上常见的甘油三酯(TG)调节剂之一,临床常与他汀联合用于调节血脂和降低心血管剩余风险。临床试验证明其除了具有确切的降低TG、低密度脂蛋白胆固醇(LDL-C)和载脂蛋白B (apo B)的作用外,还具有降低胆固醇(CHO)的作用,但针对其降低CHO的机制报道较为少见。该文从非诺贝特对CHO的合成、吸收、转运及其影响胰岛素敏感性等方面的作用调节机制进行综述。Fenofibrate is a third-generation phenoxy aryl acid derivative lipid-lowering drug,which is one of the common triglyceride (TG)modulators on the market.It is often used in combination with statins to regulate blood lipids and reduce cardiovascular risk.Clinical trials have shown that,in addition to the exact reduction of TG,low-density lipoprotein cholesterol (LDL-C)and apolipoprotein B (apo B),fenofibrate also has a cholesterol (CHO)lowering regulation effect.However,reports on its actual mechanism of reducing CHO are rare.This article reviews the mechanism of fenofibrate regulation of CHO synthesis,absorption,transportation and its influence on insulin sensitivity.

关 键 词：非诺贝特 胆固醇 机制 

分 类 号：R972.6[医药卫生—药品]